Ergoteles’s Bioventus BVS Stock Holding History

Ergoteles’s Portfolio BVS Stock Details BVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-78,860	Closed	-$228K	–	151
2023 Q2	$228K	Buy	+78,860	New	+$151K	0.01%	832
2022 Q2	–	Sell	-23,200	Closed	-$327K	–	1655
2022 Q1	$327K	Buy	+23,200	New	+$311K	0.01%	813

Other funds holding BVS

EWM

Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return

JIC

Juniper Investment Company New York $313M AUM 79.58% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KLC

Kent Lake Capital Reno, Nevada $222M AUM 18.04% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ergoteles's BVS Position: Q3 2023 in Review

Ergoteles sold out of Bioventus (BVS) in Q3 2023, closing a stake of 78,860 shares — an estimated $228K sold.

Ergoteles first reported a position in BVS in Q1 2022 and held it in 2 quarters. The position peaked at $327K in Q1 2022. 67 funds tracked by Wall St. Rank hold BVS as of Q3 2023.

Ergoteles reported no remaining Bioventus position as of Q3 2023 after selling out during the quarter.
Ergoteles sold 78,860 Bioventus shares in Q3 2023, an estimated $228K.
Ergoteles first reported a position in Bioventus in Q1 2022 and held it in 2 quarters.
Ergoteles's Bioventus position peaked at $327K in Q1 2022.
67 funds tracked by Wall St. Rank held Bioventus as of Q3 2023.

Based on Ergoteles's 13F filing for Q3 2023, filed 14 Nov 2023.